Presbyopia Global Market Report 2025

The presbyopia market size has grown strongly in recent years. It will grow from $10.11 billion in 2024 to $10.7 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to factors such as the rising prevalence of chronic diseases, an increase in eye disorders, a growing geriatric population, higher consumption of various medications, and the sedentary lifestyle of many individuals.

The presbyopia market size is expected to see strong growth in the next few years. It will grow to $13.3 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth during the forecast period can be attributed to factors such as the expansion of emerging markets, growing awareness of presbyopia treatments, increased investment in healthcare infrastructure, more drug approvals and launches, and the rising popularity of monovision LASIK surgery. Key trends expected during this period include advanced technologies, innovations in intraocular lens implants, the development of novel presbyopia treatments, the creation of cost-effective non-surgical treatments, and the use of artificial intelligence and machine learning.

The rising prevalence of vision impairment is expected to drive the growth of the presbyopia market in the coming years. Vision impairment refers to a condition where a person experiences partial or total loss of eyesight that cannot be fully corrected with glasses, contact lenses, or medical treatment. The increasing rates of vision impairment are being driven by an aging population, higher incidences of diabetes and eye diseases, prolonged screen time, and insufficient access to eye care in certain regions. Presbyopia is a major factor contributing to vision impairment, as it reduces the eye's ability to focus on near objects due to age-related stiffening of the lens. This makes everyday activities, such as reading and using digital screens, more difficult without corrective solutions. For example, the United Nations Development Programme (UNDP) reported that 19,551 people were diagnosed with vision impairments in 2022, compared to 17,478 in 2021. Additionally, more than 19,000 new diagnoses have been reported in the first seven months of 2023 alone. As a result, the growing prevalence of vision impairment is fueling the expansion of the presbyopia market.

Companies in the presbyopia market are focusing on innovative solutions to improve vision and comfort, especially for aging individuals. One such advancement is the development of eye-responsive progressive lenses, which adapt to eye movements and provide seamless vision correction for presbyopia at all distances. In August 2023, Essilor, a French company specializing in ophthalmic lenses, introduced Varilux, a brand of progressive lenses designed for people with presbyopia. This product incorporates artificial intelligence (AI) to predict visual behavior based on real-life data, offering personalized vision correction and setting a new standard for managing presbyopia. These innovations are transforming the market by providing better solutions for managing this age-related condition and enhancing the quality of life for patients.

In January 2023, Bausch + Lomb, a Canadian company specializing in eye health products, acquired AcuFocus, a US-based company that focuses on developing small-aperture technologies for treating presbyopia and other vision disorders. The acquisition allows Bausch + Lomb to expand its vision care portfolio by integrating AcuFocus’ IC-8 Apthera intraocular lens (IOL), which is designed for presbyopia and cataract patients. This acquisition strengthens Bausch + Lomb's offerings in the presbyopia market and furthers their commitment to providing innovative solutions for vision care.

Major players in the presbyopia market are Johnson & Johnson Private Limited, AbbVie Inc., Abbott Laboratories, Novartis AG, Essilor International SAS, Carl Zeiss Meditec AG, Alcon Vision LLC, Bausch + Lomb Corporation, CooperVision Inc., Santen Pharmaceutical Co. Ltd., Glaukos Corporation, STAAR Surgical Company, Ziemer Ophthalmic Systems AG, LENZ Therapeutics Inc., InSight Vision Incorporated, Oculis Holding AG, Orasis Pharmaceuticals Inc., Visus Therapeutics Inc., Eyenovia Inc., and Atia Vision Inc.

North America was the largest region in the presbyopia market in 2024. The regions covered in presbyopia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the presbyopia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Presbyopia is an age-related condition where the lens of the eye loses its flexibility, making it challenging to focus on nearby objects. It usually begins around the age of 40 and progressively worsens over time. Common solutions include reading glasses, bifocals, progressive lenses, and surgical options.

The main treatment options for presbyopia are eyeglasses, contact lenses, refractive surgery, lens implants, and other alternatives. Eyeglasses are optical devices that correct vision issues such as nearsightedness, farsightedness, astigmatism, and presbyopia by using lenses mounted in a frame. Symptoms of presbyopia include eye strain, headaches, fatigue, and blurred vision. These treatments are used by various end users, such as hospitals, specialty clinics, home care settings, and other healthcare facilities.

The presbyopia market research report is one of a series of new reports that provides presbyopia market statistics, including the presbyopia industry global market size, regional shares, competitors with the presbyopia market share, detailed presbyopia market segments, market trends, and opportunities, and any further data you may need to thrive in the presbyopia industry. This presbyopia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The presbyopia market consists of revenues earned by entities by providing services such as corneal inlay procedures, refractive surgery services, and vision therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The presbyopia market includes sales of bifocal lense, multifocal contacts, refractive lens exchange (RLE), and prescription eye drops. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.